LIFEVANTAGE CORP Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $84.00K, a 42.86% decline year-over-year.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $148.00K, a 11.28% increase year-over-year.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $147.00K, a 1.38% increase year-over-year.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $133.00K, a 5.56% increase year-over-year.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for fiscal 2026 was $232.00K, a 17.14% decline from fiscal 2025.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for fiscal 2025 was $280.00K, a 3.32% increase from fiscal 2024.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for fiscal 2024 was $271.00K, a 7.54% increase from fiscal 2023.
- LIFEVANTAGE CORP stock issued during period, value, employee stock purchase plan for fiscal 2023 was $252.00K, a 32.26% decline from fiscal 2022.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $232.00K 10-K · filed 2026-08-27 | |
| 2026-03-31 | $84.00K 10-Q · filed 2026-05-06 | |
| 2025-09-30 | $148.00K 10-Q · filed 2026-05-06 | |
| 2025-06-30 | $280.00K 10-K · filed 2026-08-27 | |
| 2025-03-31 | $147.00K 10-Q · filed 2026-05-06 | |
| 2024-09-30 | $133.00K 10-Q · filed 2026-05-06 | |
| 2024-06-30 | $271.00K 10-K · filed 2025-09-04 | |
| 2024-03-31 | $145.00K 10-Q · filed 2025-05-06 | |
| 2023-09-30 | $126.00K 10-Q · filed 2025-05-06 | |
| 2023-06-30 | $252.00K 10-K · filed 2024-08-28 | |
| 2023-03-31 | $131.00K 10-Q · filed 2024-05-02 | |
| 2022-09-30 | $121.00K 10-Q · filed 2024-05-02 | |
| 2022-06-30 | $372.00K 10-K · filed 2023-08-28 | |
| 2022-03-31 | $197.00K 10-Q · filed 2023-05-04 | |
| 2021-09-30 | $175.00K 10-Q · filed 2023-05-04 | |
| 2021-06-30 | $517.00K 10-K · filed 2022-08-23 | |
| 2021-03-31 | $271.00K 10-Q · filed 2022-05-03 | |
| 2020-09-30 | $246.00K 10-Q · filed 2022-05-03 | |
| 2020-06-30 | $653.00K 10-K · filed 2022-08-23 | |
| 2020-03-31 | $314.00K 10-Q · filed 2021-04-29 | |
| 2019-09-30 | $339.00K 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |